Related Experiment Video
Updated: Sep 30, 2025
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples
Yuri Laguna Terai1, Chun Huang2, Baoli Wang3
1Complete Omics Inc., Baltimore, MD 21227, USA.
Abstract:
The presentation of neoantigens on the cell membrane is the foundation for most cancer immunotherapies. Due to their extremely low abundance, analyzing neoantigens in clinical samples is technically difficult, hindering the development of neoantigen-based therapeutics for more general use in the treatment of diverse cancers worldwide. Here, we describe an integrated system, "Valid-NEO", which reveals patient-specific cancer neoantigen therapeutic targets from minute amounts of clinical samples through direct observation, without computer-based prediction, in a sensitive, rapid, and reproducible manner. The overall four-hour procedure involves mass spectrometry analysis of neoantigens purified from tumor samples through recovery of HLA molecules with HLA antibodies. Valid-NEO could be applicable to the identification and quantification of presented neoantigens in cancer patients, particularly when only limited amounts of sample are available.
Insights
Valid-NEO directly identifies patient-specific neoantigens from minimal clinical samples, overcoming challenges in cancer immunotherapy development. This rapid, reproducible method aids in discovering neoantigen targets for diverse cancer treatments.
Area of Science:
- Oncology
- Immunology
- Analytical Chemistry
Background:
- Neoantigens presented on the cell membrane are crucial for cancer immunotherapies.
- Analyzing low-abundance neoantigens in clinical samples is a significant technical challenge.
- This difficulty hinders the broad application of neoantigen-based therapeutics for various cancers.
Purpose of the Study:
- To introduce Valid-NEO, an integrated system for identifying patient-specific neoantigen therapeutic targets.
- To enable direct observation and analysis of neoantigens without computational prediction.
- To provide a sensitive, rapid, and reproducible method for neoantigen discovery from limited clinical samples.
Main Methods:
- Direct observation and mass spectrometry analysis of neoantigens.
- Purification of neoantigens from tumor samples via recovery of HLA molecules using HLA antibodies.
- An integrated four-hour procedure for neoantigen identification and quantification.
Main Results:
- Valid-NEO successfully reveals patient-specific cancer neoantigen therapeutic targets.
- The system operates with high sensitivity, speed, and reproducibility.
- It effectively analyzes minute amounts of clinical samples.
Conclusions:
- Valid-NEO offers a novel approach to neoantigen identification and quantification.
- The system is particularly valuable for patients with limited sample availability.
- It has the potential to advance the development and application of neoantigen-based cancer immunotherapies worldwide.
